DrugPatentWatch Database Preview
Drugs in Development Information for Aldoxorubicin
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for Aldoxorubicin?
Aldoxorubicin is an investigational drug.
There have been 17 clinical trials for Aldoxorubicin.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2014.
The most common disease conditions in clinical trials are Sarcoma, Pancreatic Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are CytRx, NantKwest, Inc., and ImmunityBio, Inc.
There are two US patents protecting this investigational drug and eleven international patents.
Summary for Aldoxorubicin
| US Patents | 2 |
| International Patents | 11 |
| US Patent Applications | 8 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2014-01-01) |
| Vendors | 17 |
Recent Clinical Trials for Aldoxorubicin
| Title | Sponsor | Phase |
|---|---|---|
| Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer | ImmunityBio, Inc. | Phase 2 |
| QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | NantKwest, Inc. | Phase 2 |
| QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer | NantKwest, Inc. | Phase 2 |
Clinical Trial Summary for Aldoxorubicin
Top disease conditions for Aldoxorubicin
Top clinical trial sponsors for Aldoxorubicin
US Patents for Aldoxorubicin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Aldoxorubicin | Start Trial | Anthracycline formulations | CytRx Corporation (Los Angeles, CA) | Start Trial |
| Aldoxorubicin | Start Trial | Combinations of albumin-based drug delivery systems | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Aldoxorubicin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Aldoxorubicin | Australia | 2013359048 | 2032-12-13 | Start Trial |
| Aldoxorubicin | Canada | 2894548 | 2032-12-13 | Start Trial |
| Aldoxorubicin | European Patent Office | 2931042 | 2032-12-13 | Start Trial |
| Aldoxorubicin | Hong Kong | 1209973 | 2032-12-13 | Start Trial |
| Aldoxorubicin | Japan | 2016503026 | 2032-12-13 | Start Trial |
| Aldoxorubicin | Japan | 2018165280 | 2032-12-13 | Start Trial |
| Aldoxorubicin | Japan | 2019206583 | 2032-12-13 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
